Ian Cooper

Ian Cooper

InvestorPlace Contributor

Ian Cooper has helped traders grow and protect their wealth since 1999.

Over the last 24 years, he’s taught thousands of investors how to trade news flow and herd mentality using a unique blend of technical and fundamental analysis. In fact, Cooper created the ADD News Flow Strategy, which allows us to trade the anticipation, dissemination, and the death of news flow by exploiting herd mentality.

Cooper was among the few analysts to spot the financial crisis of 2008, the top of subprime and Alt-A, the death of Lehman Brothers, Bear Stearns, and New Century Financial, and even the Dow’s collapse to 6,500, as well as its recovery. He even called for gold to rally well above $1.500 when it traded under $600.

At the moment, Cooper makes use of technical, fundamental and news analysis, to help individual investors grow their wealth. He’s a firm believer that hard work and thorough research will lead to investment success.

Recent Articles

There’s Still Time to Scoop up Virgin Galactic Stock Before It Takes Off

By Ian Cooper, InvestorPlace Contributor

The last time I weighed in on Virgin Galactic (NYSE:SPCE), I said, “With anticipation space tourism could soon take flight, coupled with bullish analyst, SPCE…

3 Lithium Stocks With Deal-Making Potential

By Ian Cooper, InvestorPlace Contributor

With big demand for lithium stocks on the heels of the EV boom, it's time to note some of the top ways to trade the trend.

This Is Why I’d Still Avoid IBio for Now

By Ian Cooper, InvestorPlace Contributor

With no real vaccine news to speak of, I’d avoid the IBIO stock for now. If they can get something going, it may be worth a look.

It’s Still Not a Good Time to Invest in Any Cruise Lines, Including Carnival

By Ian Cooper, InvestorPlace Contributor

With the coronavirus still spreading rapidly, now is not the time to buy Carnival stock.

Don’t Count Out Inovio Pharmaceuticals Stock Just Yet

By Ian Cooper, InvestorPlace Contributor

INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA.

Load More